BioPorto A/S

Biotechnology Research • Gentofte, Capital Region of Denmark, Denmark • 11-20 Employees

Company overview

Headquarters	Tuborg Havnevej 15 st., Hellerup, 2900, DK
Website	bioporto.com
Keywords	Diagnostics, Assay Development, Antibodies, IVD, Research And Develpment, Ngal Biomarker, Ngal Elisa Kits, Scientific And Pre-Clinical Drug Reserach, Lateral Flow Assay Development
Founded	2000
Employees	11-20

Key Contacts at BioPorto A/S

Donna Haire

Member Board Of Directors

Carsten Buhl

Chief Executive Officer

BioPorto A/S Email Formats

BioPorto A/S uses 2 email formats. The most common is {2char} (e.g., {2char}@bioporto.com), used 60% of the time.

Format	Example	Percentage
{2char}	{2char}@bioporto.com	60%
{first name}.{last name}	john.doe@bioporto.com	40%

About BioPorto A/S

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, visit bioporto.com or follow our LinkedIn pages: Outside the United States: https://www.linkedin.com/company/bioporto-diagnostics-a-s/ Within the US: https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

BioPorto A/S revenue & valuation

Annual revenue	$1,026,660
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,300,000
Total funding	No funding

Employees by Management Level

Total employees: 11-20

Seniority

Employees

C-Suite

Manager

Director

Employees by Department

BioPorto A/S has 6 employees across 4 departments.

Departments

Number of employees

Funding Data

BioPorto A/S has never raised funding before.

Frequently asked questions

BioPorto A/S is located in Gentofte, Capital Region of Denmark, DK.

BioPorto A/S was founded in 2000, making it 26 years old. The company has established itself as a significant player in its industry over this time.

BioPorto A/S has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at BioPorto A/S

Donna Haire

Member Board Of Directors

Carsten Buhl

Chief Executive Officer

4.8

40,000 users